



DEPARTMENT OF THE AIR FORCE
59TH MEDICAL WING (AETC)
JOINT BASE SAN ANTONIO - LACKLAND TEXAS

27 JAN 2017

MEMORANDUM FOR SGOWMP
ATTN: GERALD W. TALCOTT

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled Alcohol and Drug Use in Adolescents and Emerging Adults presented at/published to APA Symposium, Washington D.C., 3-6 August 2017 in accordance with MDWI 41-108, has been approved and assigned local file #17032.
2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.
4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

Linda Steel-Goodwin

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

1. The author must complete page two of this form:
 - a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP) ; Grants; etc.]
 - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
4. Attach a copy of your abstract, paper, poster and other supporting documentation.
5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
6. On page 2, have either your unit commander, program director or immediate supervisor:
 - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). **This should be accomplished no later than 30 days before final clearance is required to publish/present your materials.** If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.
8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. **Note:** For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDWI 41-108, *Presentation and Publication of Medical and Technical Papers*, for additional information.
11. The Joint Ethics Regulation (JER) DoD 5500.07-R, *Standards of Conduct*, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. **If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review.** To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.

If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP :

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS			
1. TO: CLINICAL RESEARCH	2. FROM: (Author's Name, Rank, Grade, Office Symbol) 59MHS/SGOWMP University of Tennessee HSC	3. GME/GHSE STUDENT: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO	4. PROTOCOL NUMBER: FWH20140105H
5. PROTOCOL TITLE: (NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.) Prevention of Alcohol Related Incidents in the US Air Force (DoD PROPOSAL# NH130002 / KLESGES)			
6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED: Alcohol and Drug Use in Adolescents and Emerging Adults			
7. FUNDING RECEIVED FOR THIS STUDY? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO FUNDING SOURCE:			
8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO			
9. IS THIS MATERIAL CLASSIFIED? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO			
10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO NOTE: If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.			
11. MATERIAL IS FOR: <input checked="" type="checkbox"/> DOMESTIC RELEASE <input type="checkbox"/> FOREIGN RELEASE CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.			
<input type="checkbox"/> 11a. PUBLICATION/JOURNAL (List intended publication/journal.)			
<input type="checkbox"/> 11b. PUBLISHED ABSTRACT (List intended journal.)			
<input type="checkbox"/> 11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)			
<input type="checkbox"/> 11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)			
<input checked="" type="checkbox"/> 11e. OTHER (Describe: name of meeting, city, state, and date of meeting.) APA Symposium, Washington, D.C., 3-6 August 2017			
12. HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO ASSIGNED FILE # _____ DATE _____			
13. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC NOTE: All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC).			
DATE January 30, 2017			
14. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email) McKenna, Lisa R., lisa.mckenna.ctr@us.af.mil			15. DUTY PHONE/PAGER NUMBER 210-292-3813
16. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript.			
LAST NAME, FIRST NAME AND M.I.	GRADE/RANK	SQUADRON/GROUP/OFFICE SYMBOL	INSTITUTION (If not 59 MDW)
a. Primary/Corresponding Author Klesges, Robert, C., PhD	Non-DoD Civ	N/A	UTHSC
b.			
c.			
d.			
e.			
17. IS A 502 ISG/JAC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO			
I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401_IP, AND 59 MDWI 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.			
18. AUTHOR'S PRINTED NAME, RANK, GRADE Talcott, Gerald, W., PhD	19. AUTHOR'S SIGNATURE TALCOTT, GERALD W. 1133058962		20. DATE December 08, 2016
21. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE Burchfield, Colin, M., Lt Col	22. APPROVING AUTHORITY'S SIGNATURE BURCHFIELD COLIN M. 1083159673		23. DATE December 08, 2016

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS		
1st ENDORSEMENT (59 MDW/SGVU Use Only)		
TO: Clinical Research Division 59 MDW/CRD Contact 292-7141 for email instructions.	24. DATE RECEIVED January 19, 2017	25. ASSIGNED PROCESSING REQUEST FILE NUMBER 17032
26. DATE REVIEWED 19 Jan 2017	27. DATE FORWARDED TO 502 ISG/JAC	
28. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES: <input checked="" type="checkbox"/> NO <input type="checkbox"/> YES If yes, give date. _____ <input type="checkbox"/> N/A		
29. COMMENTS <input checked="" type="checkbox"/> APPROVED <input type="checkbox"/> DISAPPROVED The abstract is approved.		
30. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER Rocky Calcote, PhD, Clinical Research Administrator	31. REVIEWER SIGNATURE CALCOTE.ROCKY.D.1178245844 <small>Digitally signed by CN=ROCKY D.1178245844 DN: cn=ROCKY D.1178245844, o=59 MDW/CRD, ou=59 MDW/CRD, email=rocky.d.1178245844@59mdw.com, c=US Date: 2017.01.19 13:34:12 -0500</small>	32. DATE
2nd ENDORSEMENT (502 ISG/JAC Use Only)		
33. DATE RECEIVED	34. DATE FORWARDED TO 59 MDW/PA	
35. COMMENTS <input type="checkbox"/> APPROVED (In compliance with security and policy review directives.) <input type="checkbox"/> DISAPPROVED		
36. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	37. REVIEWER SIGNATURE	38. DATE
3rd ENDORSEMENT (59 MDW/PA Use Only)		
39. DATE RECEIVED January 19, 2017	40. DATE FORWARDED TO 59 MDW/SGVU January 19, 2017	
41. COMMENTS <input checked="" type="checkbox"/> APPROVED (In compliance with security and policy review directives.) <input type="checkbox"/> DISAPPROVED		
42. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER Kevin Iinuma, SSgt/E-5, 59 MDW Public Affairs	43. REVIEWER SIGNATURE IINUMA.KEVIN.MITSUGU.1296227 613 <small>Digitally signed by CN=KEVIN MITSUGU 1296227613 DN: cn=KEVIN MITSUGU 1296227613, o=59 MDW/PA, ou=59 MDW/PA, email=kevin.mitsugu.1296227613@59mdw.com, c=US Date: 2017.01.19 14:58:57 -0500</small>	44. DATE January 19, 2017
4th ENDORSEMENT (59 MDW/SGVU Use Only)		
45. DATE RECEIVED	46. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> COULD NOT BE REACHED <input type="checkbox"/> LEFT MESSAGE	
47. COMMENTS <input type="checkbox"/> APPROVED <input type="checkbox"/> DISAPPROVED		
48. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	49. REVIEWER SIGNATURE	50. DATE

Symposium: Alcohol and Drug Use in Adolescents and Emerging Adults

Brief content description (up to 250 characters):

Chairperson (must be a member of APA):

Name: Dr. Wendy J. Lynch (also Speaker #1)
Highest educational degree: Ph.D.
Institution: University of Virginia
Department: Psychiatry and Neurobehavioral Sciences
Mailing Address: PO Box 801402, Charlottesville, VA 22904
Email: wlynch@virginia.edu
APA membership status: Fellow

Participants, in order of presentation:

Name: Dr. Christopher P. Holstege (Introduce Topic and Discussant):
Highest educational degree: MD
Institution: University of Virginia
Department: Emergency Medicine and Pediatrics
Mailing Address: PO Box 800699, Charlottesville, VA 22908
Email: d
APA membership status: ?

Name: Dr. Nassima Ait Daoud Tiouririne (Speaker #2):
Highest educational degree: MD
Institution: University of Virginia
Department: Psychiatry and Neurobehavioral Sciences
Mailing Address: PO Box 800623, Charlottesville, VA 22908
Email: NAT7B@hscmail.mcc.virginia.edu
APA membership status: ?

Name: Dr. Robert C. Klesges (Speaker #3):
Highest educational degree: PhD
Institution: University of Tennessee Health Sciences Center
Department: Preventive Medicine
Mailing Address: 66 North Pauline, Suite 633, Memphis, TN 38105
Email: rklesges@uthsc.edu
APA membership status: Fellow?
A 300-word general summary and a 300-word summary of each participant's contribution.

General Abstract (300 word limit):

Alcohol and drug use occurs at high rates beginning during adolescence with peak rates observed during emerging adulthood (ages 18–25). Drug and alcohol use during this

period poses numerous risks both for the individual (school, social, and legal problems, injuries, death), and society (e.g., economic costs, accidents involving others). Early drug use also leads to changes in brain development that may have life-long effects. The goal of this symposium is to integrate findings from a variety of disciplines, including preclinical, epidemiological, human laboratory, and clinical, to provide a better understanding of alcohol and drug use during adolescence and emerging adulthood and potential interventions.

Dr. Klesges will summarize the research on Brief Alcohol Interventions (BAIs), overview the key ingredients of a BAI intervention, and then present research on the largest BAI intervention ($n > 90,000$) ever conducted in the U.S. Military.

Lynch Neurobiology Abstract (300 word limit):

Ait Daoud Human Lab Abstract (300 word limit):

Robert C. Klesges Human Intervention Abstract (300 word limit):

Brief Alcohol Interventions (BAIs) are designed for young adults who are not interested in abstaining from alcohol but want to reduce problematic binge and episodic drinking. Well grounded in motivational interviewing and behavioral economic theory, single session BAI interventions have been validated in college settings and in some emergency room departments. Successful BAIs include personalized feedback related to drinking norms, alcohol-related risk, and information about alcohol and harm-reduction advice. Motivational interviewing counseling techniques are another common and active ingredient of BAIs. Overall, BAIs (typically a single face-to-face intervention or a computer intervention) result in self-reported decreases in drinking of 30 to 50%. Positive treatment effects have been reported up to four years post-intervention.

The purpose of this talk will be first to briefly overview the research on BAIs and discuss the common ingredients of BAI interventions. Next, the presentation will overview the largest BAI intervention ever conducted in the U.S. Military with over 90,000 active duty Airmen (they are called Airmen regardless of gender or rank) serving in the U.S. Air Force (USAF). The jointly administered USAF/University of Tennessee BAI has reduced the prevalence of Alcohol Related Incidents (breaking the law while drinking) by over 40% in advanced technical training in the USAF. We will also present a cost effectiveness analysis that documents that for every dollar invested in the BAI, the USAF saves over \$4.00 (conservative estimate) in training costs.

The implications of our findings in terms of relevance to both civilian and military populations will be discussed.

Disclaimer: The opinions expressed on this document are solely those of the authors and

do not represent an endorsement by or the views of the United States Air Force, the

Department of Defense, or the United States Government.

Disclaimer: The views expressed are those of the author(s)/presenter(s) and do not reflect the official views or policy of the Department of Defense or its Components.